Literature DB >> 16921491

Prostate cancer stem/progenitor cells: identification, characterization, and implications.

Dean G Tang1, Lubna Patrawala, Tammy Calhoun, Bobby Bhatia, Grace Choy, Robin Schneider-Broussard, Collene Jeter.   

Abstract

Several solid tumors have now been shown to contain stem cell-like cells called cancer stem cells (CSC). These cells, although generally rare, appear to be highly tumorigenic and may be the cells that drive tumor formation, maintain tumor homeostasis, and mediate tumor metastasis. In this Perspective, we first provide our insight on how a CSC should be defined. We then summarize our current knowledge of stem/progenitor cells in the normal human prostate (NHP), an organ highly susceptible to hyperproliferative diseases such as benign prostate hyperplasia (BPH) and prostate cancer (PCa). We further review the evidence that cultured PCa cells, xenograft prostate tumors, and patient tumors may contain stem/progenitor cells. Along with our discussion, we present several methodologies that can be potentially used to identify putative tumor-reinitiating CSC. Finally, we present a hypothetical model for the hierarchical organization of human PCa cells and discuss the implications of this model in helping understand prostate carcinogenesis and design novel diagnostic, prognostic, and therapeutic approaches. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 16921491     DOI: 10.1002/mc.20255

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  84 in total

Review 1.  Prostate cancer stem cell biology.

Authors:  C Yu; Z Yao; Y Jiang; E T Keller
Journal:  Minerva Urol Nefrol       Date:  2012-03       Impact factor: 3.720

2.  Arsenic-specific stem cell selection during malignant transformation.

Authors:  Erik J Tokar; Wei Qu; Jie Liu; Wei Liu; Mukta M Webber; James M Phang; Michael P Waalkes
Journal:  J Natl Cancer Inst       Date:  2010-03-25       Impact factor: 13.506

3.  Aldehyde dehydrogenases in cancer stem cells: potential as therapeutic targets.

Authors:  David W Clark; Komaraiah Palle
Journal:  Ann Transl Med       Date:  2016-12

4.  Critical and distinct roles of p16 and telomerase in regulating the proliferative life span of normal human prostate epithelial progenitor cells.

Authors:  Bobby Bhatia; Ming Jiang; Mahipal Suraneni; Lubna Patrawala; Mark Badeaux; Robin Schneider-Broussard; Asha S Multani; Collene R Jeter; Tammy Calhoun-Davis; Limei Hu; Jianhua Hu; Spiridon Tsavachidis; Wei Zhang; Sandy Chang; Simon W Hayward; Dean G Tang
Journal:  J Biol Chem       Date:  2008-07-28       Impact factor: 5.157

5.  Constant Degradation of the Androgen Receptor by MDM2 Conserves Prostate Cancer Stem Cell Integrity.

Authors:  Premkumar Vummidi Giridhar; Karin Williams; Andrew P VonHandorf; Paul L Deford; Susan Kasper
Journal:  Cancer Res       Date:  2019-01-09       Impact factor: 12.701

6.  HPMA copolymer-based combination therapy toxic to both prostate cancer stem/progenitor cells and differentiated cells induces durable anti-tumor effects.

Authors:  Yan Zhou; Jiyuan Yang; Johng S Rhim; Jindřich Kopeček
Journal:  J Control Release       Date:  2013-09-14       Impact factor: 9.776

Review 7.  Current mouse and cell models in prostate cancer research.

Authors:  Xinyu Wu; Shiaoching Gong; Pradip Roy-Burman; Peng Lee; Zoran Culig
Journal:  Endocr Relat Cancer       Date:  2013-06-24       Impact factor: 5.678

Review 8.  Epigenetic gene regulation in stem cells and correlation to cancer.

Authors:  Lesley A Mathews; Francesco Crea; W L Farrar
Journal:  Differentiation       Date:  2009-05-14       Impact factor: 3.880

9.  Oct4A is expressed by a subpopulation of prostate neuroendocrine cells.

Authors:  Paula Sotomayor; Alejandro Godoy; Gary J Smith; Wendy J Huss
Journal:  Prostate       Date:  2009-03-01       Impact factor: 4.104

10.  The cancer stem cell concept in progression of head and neck cancer.

Authors:  Zhuo Georgia Chen
Journal:  J Oncol       Date:  2009-12-03       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.